Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBT Margin (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed EBT Margin for 15 consecutive years, with 13.78% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 8998.0% to 13.78% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 16.83% through Dec 2025, up 1569.0% year-over-year, with the annual reading at 16.83% for FY2025, 1569.0% up from the prior year.
  • EBT Margin for Q4 2025 was 13.78% at Gyre Therapeutics, down from 24.96% in the prior quarter.
  • The five-year high for EBT Margin was 416.23% in Q4 2021, with the low at 1830.73% in Q1 2022.
  • Average EBT Margin over 5 years is 335.15%, with a median of 14.6% recorded in 2024.
  • The sharpest move saw EBT Margin tumbled -150359bps in 2021, then skyrocketed 185588bps in 2023.
  • Over 5 years, EBT Margin stood at 416.23% in 2021, then tumbled by -105bps to 22.46% in 2022, then plummeted by -1544bps to 369.38% in 2023, then skyrocketed by 79bps to 76.2% in 2024, then soared by 118bps to 13.78% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 13.78%, 24.96%, and 8.36% for Q4 2025, Q3 2025, and Q2 2025 respectively.